Request to Join
has invited you to join this group
Discussions
There are currently no active discussions.
Please check out
our archive of past discussions.
Upcoming Discussions
-
Less than
1 day
left
LeftBegins in
less than
1 day
Begins in
Ended
Ongoing
FollowThis discussion centers on using checkpoint inhibitors to manage squamous cell carcinoma of the head and neck (SCCHN).
-
Moderators
-
Professor, hematology & medical oncology and Department of Otolaryngology; Director, Head and Neck Medical Oncology ProgramNabil Saba
Professor, hematology & medical oncology and Department of Otolaryngology; Director, Head and Neck Medical Oncology ProgramProfessor, hematology & medical oncology and Department of Otolaryngology; Director, Head and Neck Medical Oncology Program
-
Experts
-
Associate Director, Moore Cancer Center; Professor of MedicineEzra Cohen
Associate Director, Moore Cancer Center; Professor of MedicineAssociate Director, Moore Cancer Center; Professor of Medicine
-
Google
